Combined advanced prostate cancer treatments: are they additive?
Combined advanced prostate cancer treatments: are they additive?
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
More than 50 clinical trials are currently exploring the combination of immunotherapy and other approved treatments for advanced prostate cancer. The results from a phase II trial of sipuleucel-T with or without radium-223 in patients with metastatic castration-resistant prostate cancer were recently published with intriguing findings.
Alternative Titles
Full title
Combined advanced prostate cancer treatments: are they additive?
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2504776331
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2504776331
Other Identifiers
ISSN
1759-4812
E-ISSN
1759-4820
DOI
10.1038/s41585-021-00459-z
